Dotterbolaget Vicore Pharma substans C21 uppmärksammas på ESH konferens
Compound 21 ”C21” som har utvecklats av Mintage Scientifics dotterbolag Vicore Pharma, kommer att få stor uppmärksamhet under European Meeting on Hypertension and Cardiovascular Prevention (ESH) den 17-20 juni i Milano. Fem muntliga presentationer från de prekliniska resultaten med C21 kommer att presenteras.
Forskningsresultaten som presenteras påvisar både C21:s effekt på kärl- och nervvävnad samt metaboliska parametrar i modeller på diabetes.
ORANGE HALL 3
Oral Session 1D
OBESITY
Saturday, June 18, 09.00 - 11.00
9.40
977 ANGIOTENSIN AT2R STIMULATION IMPROVES GLUCOSE TOLERANCE AND INSULIN SENSITIVITY IN OBESE MICE
S. Wardat (1), M. Iwai (2), M. Horiuchi (2), B. Dahlöf (3), A. Hallberg (4), T. Unger (1), U. Kintscher (1), U.M. Steckelings (1), A. Foryst-Ludwig (1)(1) Charité - Universitätsmedizin Berlin, Berlin-GERMANY, (2) Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime-JAPAN, (3) Sahlgrenska University Hospital/Östra, Gothenburg-SWEDEN, (4) Uppsala University, Uppsala-SWEDEN,
AUDITORIUM
Oral Session 4A
THERAPEUTIC ASPECTS
Sunday, June 19. 09.00 - 11.00
10.00
1068 DIRECT ANGIOTENSIN AT2-RECEPTOR STIMULATION IMPROVES SURVIVAL AND NEUROLOGICAL OUTCOME IN EXPERIMENTAL STROKE (MCAO) IN MICE
K. SCHWENGEL (1), C. Thöne-Reineke (1), K. Lucht (1), P. Namsolleck (1), S. Müller (2), M. Horiuchi (3), M. Iwai (3), B. Dahlöf (4), A. Hallberg (5), T. Unger (1), U.M. Steckelings (1)
(1) Center for Cardiovascular Research, CCR, Charité Universitätsmedizin Berlin, Berlin-GERMANY, (2) Charité Universitätsmedizin Berlin, Center for Stroke Research Berlin (CSB), Berlin-GERMANY, (3) Ehime University School of Medicine, Department of Molecular and Cellular Biology, Ehime-JAPAN, (4) Sahlgrenska University Hospital/Östra, Gothenburg-SWEDEN, (5) Uppsala University, Department of Medicinal Chemistry, Uppsala-SWEDEN,
GREEN HALL 1
Oral Session 5D
BASIC PHARMACOLOGICAL ASPECTS
Sunday, June 19, 11.00 - 12.30
11.20
819 THE MODULATION OF AORTIC THICKENING AND STIFFNESS IN L-NAME-INDUCED HYPERTENSION: THE ROLE OF AT2 RECEPTOR STIMULATION
S. BECKER (1), K. Schwengel (1), K. Lucht (1), S. Slavic (1), E. Kaschina (1), J. Leonhardt (1), J. Baulmann (2), Th. Unger (1), U.M. Steckelings (1), L. Paulis (3) (1) CENTER FOR CARDIOVASCULAR RESEARCH, CHARITE, BERLIN-GERMANY, (2) Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Würzburg-GERMANY, (3) Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava-SLOVAK REPUBLIC,
ORANGE HALL 3
Oral Session 6D
RENIN ANGIOTENSIN SYSTEM AND VASOACTIVE SUBSTANCES
Sunday, June 19, 15.30 - 17.00
15.30
370 COMPOUND 21 INDUCES VASORELAXATION VIA AN ENDOTHELIUM- AND ANGIOTENSIN II TYPE 2 RECEPTOR-INDEPENDENT MECHANISM
J. VAN ESCH (1), K. VERDONK (1), W. BATENBURG (1), E. MOLTZER (1), R. VAN VEGHEL (1), T. UNGER (2), U. STECKELINGS (2), A. DANSER (1)(1) ERASMUS MC, ROTTERDAM-THE NETHERLANDS, (2) CHARITÉ-UNIVERSITÄTSMEDIZIN BERLIN, BERLIN-GERMANY
15.40
694 CHANGES IN BAROREFLEX CONTROL OF HEART RATE PRODUCED BY CENTRAL INFUSION OF THE NOVEL NONPEPTIDE AT2 RECEPTOR AGONIST, COMPOUND 21
D. VILLELA (1), M. CAMPAGNOLE-SANTOS (2), T. UNGER (3), U. STECKELINGS (3), R. SANTOS (2)
(1) CHARITE/UFMG, BERLIN-GERMANY, (2) UFMG, BELO HORIZONTE-BRAZIL, (3) CHARITE, BERLIN-GERMANY
För anmälan och mer information!
http://www.eshmilan.org/
Taggar: